Walking after stroke is often described as requiring excessive muscle co-contraction, yet, evidence that co-contraction is a ubiquitous motor control strategy for this population remains inconclusive. Co-contraction, the simultaneous activation of agonist and antagonist muscles, can be assessed with electromyography (EMG) but is often described qualitatively. Here, our goal is to determine if co-contraction is associated with gait impairments following stroke. Fifteen individuals with chronic stroke and nine healthy controls walked on an instrumented treadmill at self-selected speed. Surface EMGs were collected from the medial gastrocnemius (MG), soleus (SOL), and tibialis anterior (TA) of each leg. EMG envelope amplitudes were assessed in three ways: (1) no normalization, (2) normalization to the maximum value across the gait cycle, or (3) normalization to maximal M-wave. Three co-contraction indices were calculated across each agonist/antagonist muscle pair (MG/TA and SOL/TA) to assess the effect of using various metrics to quantify co-contraction. Two factor ANOVAs were used to compare effects of group and normalization for each metric. Co-contraction during the terminal stance (TSt) phase of gait is not different between healthy controls and the paretic leg of individuals post-stroke, regardless of the metric used to quantify co-contraction. Interestingly, co-contraction was similar between M-max and non-normalized EMG; however, normalization does not impact the ability to resolve group differences. While a modest correlation is revealed between the amount of TSt co-contraction and walking speed, the relationship is not sufficiently strong to motivate further exploration of a causal link between co-contraction and walking function after stroke. Co-contraction does not appear to be a common strategy employed by individuals after stroke. We recommend exploration of alternative EMG analysis approaches in an effort to learn more about the causal mechanisms of gait impairment following stroke.
BackgroundDifficulty advancing the paretic limb during the swing phase of gait is a prominent manifestation of walking dysfunction following stroke. This clinically observable sign, frequently referred to as ‘foot drop’, ostensibly results from dorsiflexor weakness.ObjectiveHere we investigated the extent to which hip, knee, and ankle motions contribute to impaired paretic limb advancement. We hypothesized that neither: 1) minimal toe clearance and maximal limb shortening during swing nor, 2) the pattern of multiple joint contributions to toe clearance and limb shortening would differ between post-stroke and non-disabled control groups.MethodsWe studied 16 individuals post-stroke during overground walking at self-selected speed and nine non-disabled controls who walked at matched speeds using 3D motion analysis.ResultsNo differences were detected with respect to the ankle dorsiflexion contribution to toe clearance post-stroke. Rather, hip flexion had a greater relative influence, while the knee flexion influence on producing toe clearance was reduced.ConclusionsSimilarity in the ankle dorsiflexion, but differences in the hip and knee, contributions to toe clearance between groups argues strongly against dorsiflexion dysfunction as the fundamental impairment of limb advancement post-stroke. Marked reversal in the roles of hip and knee flexion indicates disruption of inter-joint coordination, which most likely results from impairment of the dynamic contribution to knee flexion by the gastrocnemius muscle in preparation for swing. These findings suggest the need to reconsider the notion of foot drop in persons post-stroke. Redirecting the focus of rehabilitation and restoration of hemiparetic walking dysfunction appropriately, towards contributory neuromechanical impairments, will improve outcomes and reduce disability.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.